Hecht Beth 4
4 · Xeris Biopharma Holdings, Inc. · Filed Mar 4, 2026
Insider Transaction Report
Form 4
Hecht Beth
See Remarks
Transactions
- Sale
Common Stock
[F1][F2]2026-03-02$6.24/sh−16,567$103,380→ 1,226,607 total - Sale
Common Stock
[F1]2026-03-02$7.06/sh−100$706→ 1,226,507 total
Footnotes (2)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.920 to $6.910, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Beth Hecht|2026-03-04